iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

By WebmasterMarch 11, 2024December 12th, 2024No Comments

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

See more here

Previous PostVenatorx Pharmaceuticals Expands Senior Leadership Team
Next PostIVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostVenatorx Pharmaceuticals Expands Senior Leadership Team

Next PostIVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024